Table 2.
Clinical characteristics of subjects
| Variables | Whole group | HAART subjects | ART naive subjects | p |
|---|---|---|---|---|
| n = 235 | n = 179 | n = 56 | ||
| Known HIV infection duration (years) | 4,7 ± 3,2 | 5,3 ± 3,04 | 2,8 ± 2,9 | <0,0001 |
| Duration of HAART (months) | NA | 46,2 ± 30,08 | NA | |
| WHO stage for HIV clinical disease: | ||||
| - Stage 1 | 25 (10,6) | 12 (5,1) | 13 (5,5) | 0,39 |
| - Stage 2 | 53 (22,6) | 21 (8,9) | 32 (13,6) | 0,93 |
| - Stage 3 | 140 (59,6) | 129 (54,9) | 11 (4,7) | 0,0039 |
| - Stage 4 | 17 (7,2) | 17 (7,2) | 0 | <0,0001 |
| Body mass index (kg/m2) | 22,3 ± 3,8 | 22,5 ± 3,9 | 21,7 ± 3,4 | 0,198 |
| SBP (mmHg) | 118,82 ± 20,89 | 120,58 ± 21,7 | 113,2 ± 16,7 | 0,023 |
| DBP (mmHg) | 77,7 ± 14,02 | 79,8 ± 14,7 | 71,8 ± 11,6 | 0,0002 |
| HAART regimen: | ||||
| AZT + 3TC + NVP | NA | 164 (94,8) | NA | |
| d4T + 3TC + NVP | NA | 3 (1,6) | NA | |
| ABC + DDI + Lp/r | NA | 9 (5) | NA | |
| TDF + 3TC + EFV | NA | 3 (1,6) | NA |
HTA = hypertension; BMC = body mass index; SBP = Systolic blood pressure; DBP = diastolic blood pressure; CKD = chronic kidney disease; HAART: Highly active antiretroviral therapy. NA: not applicable; d4T: stavudine, 3TC: lamivudine, NVP: nevirapine, ABC: abacavir, DDI: didanosine, Lp/r : lopinavir/ritonavir, EFV: efavirenz, TDF: tenofovir.